Core Insights - Windtree Therapeutics, Inc. has announced the issuance of a patent in Japan for aPKCi inhibitors aimed at treating hedgehog pathway-dependent cancers, with the patent number 7603605 expiring in 2040 [1][2][3] Company Overview - Windtree Therapeutics is a biotechnology company focused on developing innovative therapies for critical conditions and diseases, with a portfolio that includes istaroxime for acute heart failure and preclinical aPKCi inhibitors for oncology applications [4] Product Development - The aPKCi inhibitor platform is a high-potency drug candidate with applications in treating various cancers, including basal cell carcinoma and small cell lung cancer, and includes both topical and oral formulations developed in collaboration with Cancer Research UK [2][3] - The company is also pursuing additional patent applications for crystalline forms of aPKCi inhibitors for cancer treatment [3] Strategic Direction - The issuance of the new patent is a significant part of the company's development strategy, with plans to expand its intellectual property portfolio in key global markets [3]
Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology Pipeline